07:35 AM EST, 12/03/2025 (MT Newswires) -- Pharvaris ( PHVS ) said Wednesday that a global phase 3 study of its investigational therapy deucrictibant met the primary endpoint of rapid symptom relief as well as all secondary efficacy endpoints in patients suffering acute hereditary angioedema attacks.

In the study, patients taking 20 milligram deucrictibant immediate-release capsules began to feel symptom relief in 1.28 hours after an attack compared with 12 hours for those receiving placebo, the company said.

Patients who took the medicine also experienced an end of attack progression after an average of 17.47 minutes compared with 228.67 minutes for placebo, and complete symptom resolution in 11.95 hours compared with more than 24 hours for placebo, the company said.

The company said the data from the 134-patient study will be used for marketing authorization applications anticipated to be submitted in H1 of 2026.

Shares of the company were up more than 19% in recent premarket activity Wednesday.